BioPharma Dive April 22, 2024
For patients diagnosed with rare diseases or chronic illnesses, treatment delays can seriously impact health outcomes. A meta-analysis of cancer outcomes, for example, found that every four-week delay in treatment is associated with a 6% to 8% increased chance of death for patients with any of five major tumor types.
And in many specialties, those delays are increasing. In the five years ending in 2022, wait times for appointments with cardiologists in large metropolitan regions shot up 26%.
One way healthcare stakeholders, including biopharma companies, can shorten patients’ time to therapy? Help them find and access appropriate specialists as early as possible in the treatment journey.
Of course, finding the right match can be a difficult task, particularly for patients...
Today's Sponsors
Today's Sponsor